Topic: cardiovascular outcomes
One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.
Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.
In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.
Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.
AstraZeneca’s Farxiga is chasing an OK to treat heart failure regardless of a diabetes diagnosis. But in the meantime, it's scored a smaller nod.
Now that AstraZeneca has scored its Farxiga outcomes data, it's beefing up its sales team to prepare for an expanded FDA approval.
AstraZeneca's Farxiga has new CV data that could help the entire SGLT2 class—and even pressure heart medicines outside the class, too.
AstraZeneca is still stinging after its SGLT2 drug Farxiga was waved off in Type 1 diabetes, but new heart failure data could ease the pain.
Amarin’s Vascepa has ridden a wave of good news as it approached a label expansion review. Now, a bit of bad news: the FDA wants a closer look.
Amarin is doubling down on its heart drug Vascepa, aiming to raise $400 million-plus in a stock offering. But investors aren't thrilled with the idea.